Coherus Oncology (CHRS) Change in Acquisitions & Divestments (2017 - 2026)

Coherus Oncology has reported Change in Acquisitions & Divestments for 9 years, with the latest figure at $38.1 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments changed N/A year-over-year to $38.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.5 million (changed N/A YoY) and the FY2025 annual result came in at $21.5 million, up 246.16% from the prior year.
• Change in Acquisitions & Divestments climbed to $38.1 million in Q1 2026 per CHRS's latest filing, from $19.8 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $131.1 million in Q4 2023 and troughed at -$4.2 million in Q2 2023.
• A 4-year average of $26.1 million and a median of $11.8 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2024 and 2025: Change in Acquisitions & Divestments tumbled 101.9% in 2024, then soared 896.3% in 2025.
• Over 4 years, Change in Acquisitions & Divestments stood at $131.1 million in 2023, then sank by 101.9% to -$2.5 million in 2024, then jumped by 896.3% to $19.8 million in 2025, then surged by 92.48% to $38.1 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $38.1 million, $19.8 million, and -$2.5 million for Q1 2026, Q4 2025, and Q4 2024 respectively.